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ABSTRACT
Lantibiotics are ribosomally synthesized peptide antibiotics composed of an N-terminal leader peptide that is cleaved to yield the
active antibacterial peptide. Significant advancements in molecular tools that promote the study of lantibiotic biosynthesis can
be used in Streptococcus mutans. Herein, we further our understanding of leader peptide sequence and core peptide structural
requirements for the biosynthesis and transport of the lantibiotic mutacin 1140. Our study onmutacin 1140 biosynthesis shows
a dedicated secondary cleavage site within the leader peptide and the dependency of transport on core peptide posttranslational
modifications (PTMs). The secondary cleavage site on the leader peptide is found at the9 position, and secondary cleavage oc-
curs before the core peptide is transported out of the cell. The coordinated cleavage at the9 position was absent in a lanT dele-
tion strain, suggesting that the core peptide interaction with the LanT transporter enables uniform cleavage at the9 position.
Following transport, the LanP protease was found to be tolerant to a wide variety of amino acid substitutions at the primary
leader peptide cleavage site, with the exception of arginine at the1 position. Several leader and core peptide mutations pro-
duced core peptide variants that had intermediate stages of PTM enzymemodifications, supporting the concept that PTM en-
zymemodifications, secondary cleavage, and transport are occurring in a highly coordinated fashion.
IMPORTANCE
Mutacin 1140 belongs to the class I lantibiotic family of ribosomally synthesized and posttranslationally modified peptides
(RiPPs). The biosynthesis of mutacin 1140 is a highly efficient process which does not lead to a discernible level of production of
partially modified core peptide variants. The products isolated from an extensive mutagenesis study on the leader and core pep-
tides of mutacin 1140 show that the posttranslational modifications (PTMs) on the core peptide occur under a highly coordi-
nated dynamic process. PTMs are dictated by the distance of the core peptide modifiable residues from PTM enzyme active sites.
The formation of lanthionine rings aids in the formation of successive PTMs, as was observed in a peptide variant lacking a C-
terminal decarboxylation.
Lantibiotics are a class of ribosomally synthesized peptide antibiot-ics producedbyGram-positivebacteria, suchasLactococcus lactis
and Streptococcus mutans (1, 2). Lantibiotics are characterized by
the presence of posttranslational modifications (PTMs), such as
dehydrated residues and lanthionine rings. Themodified residues
2,3-didehydroalanine (Dha) and 2,3-didehydrobutyrine (Dhb)
are formed from dehydration of serines and threonines, respec-
tively. The cyclization between a cysteine and either a Dha or a
Dhb forms a lanthionine or a methyllanthionine ring, respec-
tively. The biosynthetic gene cluster contains all the genes neces-
sary to produce a lantibiotic. The lan operon for class I lantibiotics
contains genes encoding the lantibiotic peptide (lanA); the dehy-
dratase (lanB), responsible for the dehydration of serine and thre-
onine residues; the cyclase (lanC), responsible for the stereospe-
cific formation of the thioether linkages; and an ABC-like
transporter (lanT) for the export of the modified peptide. The
mutacin 1140 operon also contains an additional gene called lanD,
which is essential for the C-terminal decarboxylation of the core
peptide, forming an aminovinyl-cysteine residue (3). Lantibiotics
contain a leader peptide sequence that is cleaved by a dedicated
protease called LanP following posttranslationalmodifications (4,
5). The substrate specificity of LanP varies among lantibiotics (6).
In most lantibiotic systems, LanP is believed to be associated with
the extracellular leaflet of the membrane and cell wall (7). There-
fore, cleavage does not occur until mutacin 1140 is transported
out of the cell by LanT.
The lantibiotic mutacin 1140, produced by S. mutans JH1140,
has been shown to have a mechanism of action similar to that of
another class I lantibiotic called nisin. Mutacin 1140 and nisin
have structurally similar rings A and B (Fig. 1A), and both nisin
and mutacin 1140 bind and abduct lipid II (8–13). Mutacin 1140
has also been shown to be bactericidal to pathogenic bacteria, such
as methicillin-resistant Staphylococcus aureus (MRSA), with no
significant development of resistance (14).Mutacin 1140 is one of
a small group of peptides that is currently under preclinical devel-
opment for the treatment of Gram-positive bacterial infections
(15). Many studies have revealed that lantibiotics are structurally
diverse and have differences in activity from that of nisin. For
instance, mutacin 1140 is a class I lantibiotic like nisin. However,
the core peptide of mutacin 1140 is 12 amino acids shorter than
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that of nisin. Mutacin 1140 has the same ability to bind to lipid II,
but it does not form bacterial membrane pores like nisin does
(12, 13).
The leader peptide sequences of lantibiotics belonging to the
same class generally share structural motifs related to their func-
tion. The mutacin 1140 leader peptide sequence is unique among
class I lantibiotics in that its primary sequence has little similarity
to that of other class I lantibiotics (Fig. 1B). However, the struc-
ture of the leader peptide of mutacin 1140 is similar to that of the
leader peptide of mutacins produced by other S. mutans strains
(16–18). Furthermore, there are considerable differences in leader
peptide sequences among lantibiotics with similar core peptide
structures. The leader peptide sequence is between 19 and 48
amino acid residues long (6, 19). Due to the vast differences
among leader peptide sequences, the findings of studies of the
actual function of the leader peptide sequence during lantibiotic
biosynthesis have been inconsistent. It has been suggested that the
leader peptide sequence is a signal for transport, inactivates the
peptide to protect the producing strain, and provides recognition
for PTM enzymes (20–22). Conserved motifs that provide a rea-
sonable basis for the classification of lantibiotics are found in some
leader peptides. The commonmotif found in class I lantibiotics is
the F(N/D)LD box (Fig. 1B), which some studies show is impor-
tant for the maturation of the core peptide antibiotic (19, 20, 23).
Class II lantibiotics contain aGGorGAwhich is used as a cleavage
site for the removal of the leader peptide from the core peptide and
contain an upstream EV and/or EL conserved sequencemotif (24,
25). Amino acid substitutions in the conserved regions within the
leader peptide have shown that the composition of these common
motifs is important for thematuration of the core peptide, while a
vast majority of the leader peptide does not have any amino acid
sequence specificity (19, 20, 26, 27). Solution nuclear magnetic
resonance studies have shown that the leader peptide sequence
lacks secondary structure (28), while the cocrystal structure of
NisB in complex with the substrate peptideNisA shows an antipa-
rallel  strand (29). It is likely that the leader peptide remains
unstructured until it binds to the PTM enzymes. However, addi-
tional studies are needed to verify this assumption. Experimental
studies suggest that the leader peptide is important for interacting
with the dehydratase LanB, the cyclase LanC, and the transporter
FIG 1 Lantibiotic structural elements. (A) Covalent structures for nisin and mutacin 1140, with the lanthionine rings labeled from the N terminus to the C
terminus. (B) Leader peptide sequence alignments of structurally related class I lantibiotics, i.e., nisin produced by Lactococcus lactis, subtilin produced byBacillus
subtilis, epidermin produced by Staphylococcus epidermidis, gallidermin produced by Staphylococcus gallinarum, Pep5 produced by Staphylococcus epidermidis,
epilancin K7 produced by Staphylococcus epidermidis, mutacin Ny266 produced by S. mutansNy266, mutacin III produced by S. mutansUA787, mutacin 1140
produced by S. mutans JH1140, and, for comparison, lacticin 481 (a class II lantibiotic) produced by Lactococcus lactis (16, 18, 47–53). In the sequences, the
F(N/D)LD box and C-terminal proline in class I lantibiotics are underlined and in bold, respectively. The EV and ELmotifs and the GA cleavage site of the class
II lantibiotic lacticin 481 are in bold. (C) Secondary structure prediction for the mutacin 1140 leader peptide using SOPMA. h, alpha helix; e, extended strand;
c, random coil; t, beta turn. Alpha-helical regions are underlined, while random coils in the leader peptide sequence are in bold.
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LanT (30, 31). However, these studies are challenged by the failure
to distinguish betweenwhich of the proposed leader peptide func-
tions are affected by the changes in amino acid residues.
The biosynthesis of mutacin 1140 shares some important fea-
tures with the biosynthesis of other lantibiotic systems; however,
there are considerable differences between the biosynthesis ofmu-
tacin 1140 and nisin. In this study, we identify a secondary cleav-
age site within the leader peptide. We also show relaxed substrate
specificity for the LanP protease and show that primary cleavage is
not dependent on the leader peptide sequence. Observations were
made from several leader and core peptidemutations and support
the concept that the core peptide is not being shuttled between
PTM enzymes and the transporter by the leader peptide. Mutacin
1140 biosynthesis is a dynamic process in which PTM enzyme
modifications and transport are occurring in a highly coordinated
fashion, supporting the hypothesis that leader peptide binding at a
single locus is sufficient for coordinating PTM enzyme modifica-
tions and transport.
MATERIALS AND METHODS
Bacterial strains, plasmids, and media. The bacterial strains and plas-
mids used in this study are listed in Table 1. The cloning strain Escherichia
coli DH5 (Invitrogen, Carlsbad, CA) was cultured at 37°C on Luria-
Bertani (LB) broth or agar. THyex broth (30 g/liter Todd-Hewitt broth, 3
g/liter yeast extract), THyex agar medium (30 g/liter Todd-Hewitt broth,
3 g/liter yeast extract, 15 g/liter Bacto agar [Becton, Dickinson and Com-
pany, Franklin Lakes, NJ]), and top agarmedium (30 g/liter Todd-Hewitt
broth, 3 g/liter yeast extract, 7.5 g/liter Bacto agar [Becton, Dickinson and
Company]) were used to culture S. mutans JH1140 (ATCC 55676) and
Micrococcus luteus ATCC 10240 at 37°C. S. mutans ATCC 55676 lanP
was obtained from Oragenics Inc.
Mutagenesis leader peptide. The S. mutans genome database and lan
gene cluster (GenBank/EMBL accession number AF051560) were used to
design primers for the mutagenesis and sequencing work. pIFDC2 (32) is
an in-frame-deletion (IFD) cassette vector which uses a highly expressed
constitutive promoter to drive the expression of a synthetic operon con-
taining both a positive selectionmarker (ermAM) and a negative selection
marker (pheS*) (33). Fragments consisting of 500 bp of DNA up-
stream of lanA (primers MutA-UpF and MutA-UpR-IDH) and500 bp
of DNA downstream of lanA (primers MutA-DnF-erm and MutA-DnR)
were amplified. These DNA fragments were attached to the 5= and 3= ends
of the IFDC2 cassette, respectively. Transformation of this PCR-amplified
product with S. mutans JH1140 ATCC 55676 or S. mutans lanP gener-
ated S. mutans strain lanA/IFDC2 and S. mutans strain lanA/IFDC2
lanP (Table 1). The S. mutans natural competence pathway was used for
transforming PCR and plasmid products. Natural competence can be
activated using a competence-stimulating peptide (CSP) (34). An over-
night culture of either S. mutans strain lanA/IFDC2 or S. mutans strain
lanA/IFDC2 lanPwas diluted to an optical density at 600 nm (OD600) of
0.1 and grown to an OD600 of 0.25 before the addition of 2l of 10g/ml
TABLE 1 Strains and plasmids used in this study
Straina Plasmid intermediateb Relevant characteristic(s) Reference or source
S. mutans
JH1140 (ATCC 55676) Wild-type bacteriocin-producing strain 17 (strain)
lanA/IFDC2 pIFDC2 Gene replacement strain 32 (plasmid)
lanP pIFDC2 planP lanP deletion strain This study
lanT pIFDC2 planT lanT deletion strain This study
lanP lanT pIFDC2 planP planT lanP and lanT deletion strain This study
A(9)Fc pA(9)F Single Phe substitution at internal cleavage site This study
S(8)Pc pS(8)P Single Pro substitution at internal cleavage site This study
S(8)Fc pS(8)F Single Phe substitution at internal cleavage site This study
(8)c p(8) Single truncation at internal cleavage site This study
S(8)Ac pS(8)A Single Ala substitution at internal cleavage site This study
N(7)Pc pN(7)P Single Pro substitution at internal cleavage site This study
N(7)Ac pN(7)A Single Ala substitution before cleavage site This study
D(6)Ac pD(6)A Single Ala substitution before cleavage site This study
D(5)Ac pD(5)A Single Ala substitution before cleavage site This study
P(4)Ac pP(4)A Single Ala substitution before cleavage site This study
P(4)A F(1)S p P(4)A F(1)S Ala substitution before cleavage site and Ser
substitution after cleavage site
This study
D(3)Ac pD(3)A Single Ala substitution before cleavage site This study
T(2)Ac pT(2)A Single Ala substitution before cleavage site This study
R(1)Ac pR(1)A Single Ala substitution at primary cleavage site This study
R(1)H* pR(1)H Single His substitution at primary cleavage site This study
C6Hisc pC6His 6His substitution before primary cleavage site This study
C(7)A pC(7)A Disruption of ring A formation This study
C(11)A pC(11)A Disruption of ring B formation This study
C(21)A pC(21)A Disruption of ring C formation This study
S(19)A pS(19)A Disruption of ring D formation This study
C(7)A C(11)A pC(7)A C(11)A Disruption of ring A and B formation This study
C(21)A S(19)A pC(21)A S(19)A Disruption of ring C and D formation This study
M. luteus ATCC 10760 Indicator strain in the different antagonism assays 35 (strain)
E. coli DH5 pCR2.1-TOPO Intermediate cloning host Invitrogen
a Unless indicated otherwise, all mutations were made in wild-type strain JH1140.
b All the plasmids came from E. coli DH5 cells.
c Mutations were made in both the wild-type strain and the lanP strain.
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CSP to 200 l of bacterial suspension. After 30 min of incubation, 1 l of
the PCR product of the IFDC2 cassette spanned by upstream and down-
streamDNAs from the structural gene (lanA) was added to the cells. After
4 to 5 h of incubation, 50 l of solution was plated on THyex plates
containing 15 g/ml of erythromycin. Colonies that grew in the presence
of erythromycin were sequenced to confirm that the IFDC2 cassette re-
placed the lanA gene. This strainwas used for subsequent transformations
of plasmids containing leader peptide mutations. Leader peptide muta-
tions were introduced into the lanA gene by 2-step PCR. The mutations
were then inserted into the pCR2.1-TOPO vector according to the proto-
col provided by the manufacturer (Invitrogen). The sequences of the
transformants approximately 300 bp upstream and downstream from
lanAwere determined by the use of primers MutAsegF andMutAseqR. S.
mutans lanA/IFDC2 was transformed by the same protocol described
above with 1l of cloned pCR2.1-TOPO vector. The transformants of the
leader peptide mutants were plated on THyex plates with 4 mg/ml of
chlorophenylalanine. Colonies growing in the presence of chloropheny-
lalanine represent those that have lost the IFDC2 cassette and have an
insertion of lanA with the expected mutation. Colonies from these plates
were identically spotted on THyex and THyex with erythromycin to re-
move false-positive colonies from the screen. Mutants were further con-
firmed by sequencing.
Deferred antagonism assay. The deferred antagonism assay was per-
formed as previously reported (35). S. mutans wild-type and mutant
strains were grown overnight in liquid culture. The next morning, the
culture was diluted to an OD600 of 0.1 and allowed to grow to mid-loga-
rithmic phase. The culture was then diluted to an OD600 of 0.05 before 2
l of the bacterial suspension was spotted on fresh prewarmed THyex
plates. Duplicates of triplicate spots were tested for each strain, with the
wild-type and lanA strains serving as positive and negative controls,
respectively. The plates were incubated for 18 h at 37°C in a candle jar. On
the next day, the bacterial colonies were heat killed at 65°C for 1.5 h and
then cooled to 37°C. M. luteus from a fresh overnight plate was used to
inoculate prewarmed THyex broth and grown to mid-logarithmic phase
at 37°C. The culture was then diluted to an OD600 of 0.2 and diluted
25-fold in prewarmed (42°C) top agar. Fivemilliliters of top agar contain-
ing the bacterial suspension was then poured onto each plate with heat-
killed bacteria, and the plate was incubated overnight at 37°C. Trypsinwas
used to remove the leader peptide from the mutacin 1140 core peptide by
adding it to the top agar at a concentration of 5 g/ml. The area for each
zone of inhibition was calculated and compared to wild-type zones of
inhibition. The Student t test was used to determine whether the differ-
ences in the activities of each mutant strain with respect to the activity of
the wild-type strain were statistically significant. The activities of the pu-
rified variants were determined using the same conditions for overlaying
the indicator strain described above, in which 5 l of the extracted vari-
ants was spotted on prewarmed THyex plates after being overlaid withM.
luteus.
Isolation ofmutacin 1140 leader peptide variants.Mutacin 1140 and
variants of mutacin 1140 were isolated as previously reported (18). A
modified THyexmediumwas used as the fermentationmedium for inoc-
ulation. The medium contained 30 g/liter Todd-Hewitt broth, 3 g/liter
yeast extract, 1 g/liter NaH2PO4, 0.2 g/liter Na2HPO4, 0.7 g/liter MgSO4,
0.005 g/liter FeSO4, 0.005 g/liter MnSO4, and 0.3% agar. Five hundred
milliliters of the semisolid fermentation medium was placed in a 1-liter
glass beaker and stab inoculated using an inoculating needle. The inocu-
lum was placed at 37°C for 72 h and then immediately frozen at 80°C.
Themediumwas then thawed in a 55°C water bath for 1 h. The inoculum
was then placed in 250-ml centrifuge bottles and centrifuged at 20,000
g for 30 min. The collected supernatant was pooled and mixed with chlo-
roform at a 1:1 ratio, and themixture was shaken vigorously. Themixture
was centrifuged again at 20,000  g for 30 min. The phase between the
aqueous and chloroform layers was collected and allowed to dry over-
night. The dried precipitate was resuspended in 35% acetonitrile and
tested by deferred antagonism assay for activity. The crude extract was run
on either a semiprep C18 column (octyldecyl silane [C18]; particle size, 5
m; 4.6 by 250 mm; Agilent Zorbax) or an analytical column, as previ-
ously reported (35). 2-Mercaptoethanol (BME) modification of mutacin
1140 peptide variantswas done as previously reported (13, 36). The lack of
PTM cyclase activity would prevent lanthionine ring formation and result
in the presence of cysteine thiols that can be selectively labeled. 1-Cyano-
4-dimethylaminopyridinium tetrafluoroborate (CDAP) and tris(2-car-
boxyethyl)phosphine (TCEP) were used to determine whether the iso-
lated products had undergone all of the PTM cyclase modifications (37).
We followed the procedure previously reported by Kluskens et al. (38)
with slight modification. We used 0.1 N hydrochloric acid to dissolve the
CDAP. As a positive control, we used an extended analog of the chemot-
actic peptide resact (LRGGGVCGPAGTVCGYGGG-NH2) (39). The pu-
rified products were confirmed by mass on a Shimadzu matrix-assisted
laser desorption ionization mass spectrometer (MALDI-MS) in both the
linear and reflectron modes.
RESULTS
LanP cleavage site. We have previously reported that substitu-
tions at the	1 position of the core peptide lead to an increase in
bioactivity or do not significantly reduce bioactivity (35). This
suggests that the presence of an F residue at position	1 [F(	1)]
is not essential for cleavage by LanP. Alignments of the cleavage
site of class I lantibiotics show a basic amino acid, such as arginine,
at the1 position of the cleavage site and a conserved proline at
the 2 or 4 position (Fig. 1B). Mutations were made to deter-
mine whether there is a recognition motif for LanP upstream of
the cleavage site. Secondary structure analysis using the self-opti-
mized prediction method with alignment (SOPMA) (40) predicts
that the N-terminal end of the leader peptide (the region from
positions32 to39) is an alpha helix, while the C-terminal end
(the region from positions1 to8) is a random coil (Fig. 1C).
Interestingly, the region from positions9 to20 of themutacin
1140 leader peptide is primarily predicted to be an extended
strand, which is in agreement with the secondary structure of the
nisin leader peptide in the cocrystal structure of NisA and NisB
(29). Given the lack of predicted secondary structure at the C-ter-
minal end of the leader peptide, LanP protease recognition would
presumably be dependent on structural elements upstream or
downstream of the primary cleavage site. First, alanine substitu-
tions were made to determine the importance of the amino acids
frompositions7 to1 of the leader peptide (Fig. 2A andB). The
T-to-A substitution at position 2 [T(2)A] resulted in a slight
reduction in activity, while the other alanine substitutions from
residues7 to3 resulted in no statistically significant decrease
in activity. The small change or the lack of a statistically signifi-
cantly reproducible reduction in activity indicates that the region
upstream of the cleavage site does not have a strict motif for pro-
teolytic activity. Interestingly, the substitution of the proline for
an alanine at the 4 position did not result in a decrease in bio-
activity. The presence of a proline near the cleavage site is con-
served among other class I lantibiotics, and the lack of any change
in bioactivity with the alanine substitution in this region suggests
that the proline is not important for the biosynthesis of mutacin
1140. We subsequently tested an alanine substitution at the R at
position 1 [R(1)A]. This mutation resulted in an approxi-
mately 90% loss of bioactivity (Fig. 2B). The R(1)A mutation
signifies the importance of arginine at this position for LanP ac-
tivity. The constructs with alanine substitutions from positions
7 to 2 were also tested in the background of a lanP deletion to
determinewhether another protease can cleave the leader peptide.
Escano et al.
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None of the substitutions in the lanP deletion strain resulted in
activity against the M. luteus indicator strain, but activity was re-
stored with the addition of trypsin to the top agar. Removal of the
leader peptide using trypsin in a LanP-deficient strain is possible,
given the presence of an Arg at the 1 position of the leader
peptide and the core peptide resistance to trypsin cleavage at the
Lys2 and Arg13 positions. Interestingly, the bioactivity was signif-
icantly greater in the lanP strain when trypsin was used to re-
move the leader peptide. Reversed-phase high-pressure liquid
chromatography (RP-HPLC) of the lantibiotic extracted from the
lanP strain yielded at least a 2-fold increase in the amount of
purified product (Fig. 3). The histidine substitution of residues at
positions 7 to 2 resulted in an 85% reduction in activity but
did not completely remove all activity. This observation suggests
that LanP is still able to process the removal of the leader peptide
containing 6 histidine substitutions, albeit at a much lower effi-
ciency. Furthermore, product could not be isolated from the cul-
ture broth, suggesting that biosynthesis or transport of the prod-
uct is drastically reducedwith histidine substitutions of residues at
positions7 to 2. A substitution of histidine at the1 position of
the leader peptide was evaluated. A histidine side chain has a pK of
6.0 and would be predominantly neutral at the physiological pH
of the medium. We introduced this mutation to determine
whether the positive charge within the 1 position was essential
for activity and figured that this idea could be tested by changing
the pHof the growthmedium.Testing ofmediumwith a lower pH
was not needed since there was no significant change in the bio-
activity of the construct with the R(1)H mutation in the me-
dium with the neutral pH. However, we cannot rule out the pos-
sible need for a positive charge at the1 position, given that the
lactic acid production by S.mutans could lower the pH around the
bacterial colony, enabling the histidine to be charged. These data
show that the LanP protease is tolerant to a wide variety of amino
acid substitutions upstreamof the primary leader peptide cleavage
site and that the R residue at position 1 is not essential for the
removal of the leader peptide.
Discovery of an additional leader peptide cleavage site.
MALDI-MS of purified products obtained from the culture broth
of the S. mutans lanP and R(1)A strains showed that it con-
tained single products with masses of 3,165 Da and 3,079 Da,
FIG 2 Identification of structural elements within the mutacin 1140 leader peptide that are important for bioactivity. (A) Covalent structure representation of
the mutations made on the leader peptide. (B to D) The bioactivities of the leader and core peptide mutants were measured as the percent difference in the zone
of inhibition between the wild-type and the mutant strains. The lanA strain was used as a negative control for bioactivity in all experiments. The change in
activity was measured for mutations near the LanP cleavage site (B), mutations within the newly discovered cleavage site (C), and mutations in the transporter
lanT and core peptide regions responsible for ring formation (D). For each mutation, the bioactivity was compared to the activity of wild-type strain S. mutans
JH1140. All the activities were determined in the absence of trypsin in the top agar of the overlays. The Student t test was used for statistical analysis, and the
asterisks signify statistical significance (P
 0.05).
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respectively (Table 2). The peptidemasses indicate the attachment
of the amino acids at positions 8 to 1 instead of the whole
41-amino-acid leader peptide to the fully modified lantibiotic, as
expected in the absence of LanP activity. This observation suggests
that an additional cleavage site exists internally within the leader
peptide between residues A(9) and S(8). The absence of any
inhibitory activity of these products also demonstrates that the
truncated leader peptide keeps mutacin 1140 in an inactive struc-
tural state. It has been shown that the biosynthesis of nisin in the
absence of LanP produces partially cleaved leader peptide prod-
ucts (41, 42), with the full-length leader peptide being the main
product (43). Unlike nisin, only a single truncated leader peptide
product is observed for the mutacin 1140 leader peptide. To fur-
ther understand the importance of the new cleavage site, point
mutations were made at the new cleavage site in the S. mutans
lanP strain. This was done in order to prevent cleavage at the
primary cleavage site, R(1). The residue at S(8) or A(9) was
replaced by either an alanine or a phenylalanine (Fig. 2A and C).
The switch to a smaller or bulkier side chain did not affect second-
ary cleavage activity, nor did it affect the bioactivity of the mutant
strains in the deferred antagonism assay when trypsin was added
(Fig. 2C). The masses of the isolated mutant products were deter-
mined, and they still indicated the attachment of the 8-amino-acid
leader peptide (Table 2). Deletion of S(8) yielded two products
withmasses of 3,063Da and 2,948Da, which correspond to partial
cleavage at N(7) and D(6), respectively. To further determine
whether the cleavage is absolutely necessary, proline mutations
were made at either S(8) or N(7). Proline mutations alter the
position of neighboring amino acids by introducing a turn in the
peptide structure. A proline mutation at S(8) shifted the cleav-
age site to I(11) or T(13), as indicated by the masses of the
isolated products (Table 2). Interestingly, N(7)P had a major
product with a cleavage site at I(11) but also hadmultipleminor
products with cleavage sites ranging from T(13) to D(6).
P(4)A had only a single product that had no shift in the cleavage
site between A(9) and S(8) (Table 2). The structural region of
the peptide at P(4) is not important for the alignment of the
peptide to be cleaved at the new secondary cleavage site. The struc-
tural region for aligning the peptide for cleavage presumably oc-
curs upstream of the P(4) position. We have previously shown
that a serine engineered at the	1 position does not undergo de-
hydration (35), suggesting that the distance from either the LanP
or the new cleavage site is important for a dehydration modifica-
tion. We engineered a P(4)A F(1)S mutant to determine if the
proline substitutionwould enable dehydration at the	1 position.
Themasses of the identified peptide products in the wild-type and
lanP deletion strains were 2,205 and 3,078 Da, respectively, which
correspond to products that aremissing dehydration. This finding
suggests that the P(4)A substitution did not promote dehydra-
tion at the	1 position and that the length from the	1 position
appears to be important for the dehydratase activity. Interestingly,
the double mutation resulted in an 35% reduction in activity,
whereas the P(4)A and F(1)S mutations individually resulted in
no loss in activity. There was no cyanylation of free thiols by
CDAP in the P(4)A F(1)S mutant, suggesting that all lanthio-
nine rings were formed by the cyclase.
Given that a deletion of S(8) shifted the cleavage site down-
stream to N(7) and D(6), we decided to investigate a larger
deletion downstream of S(8). The mutant with the deletion of
positions 7 to 2 [the (7–2) mutant] was engineered in the
wild-type strain and in the lanP deletion strains. The deferred
antagonism assay for each of these strains showed that they had no
bioactivity (Fig. 2A and C and 4A). Products were isolated from
the culture liquor of thesemutants and were characterized to have
two predominant masses of 1,936 and 2,508 Da. The 2,508-Da
product corresponds to the mutacin 1140 peptide that has under-
gone all of the posttranslational modifications with a short leader
peptide of S(2) and R(1). Interestingly, the 2,508-Da product
was present in both the wild-type strain and the lanP deletion
strains. This suggests that LanP is not capable of processing the
truncated (SR) leader peptide in this mutant strain. Trypsin was
added to the extracted products to determine whether activity
could be restored. The trypsin-digested product did have inhibi-
tory activity in our bioassay (Fig. 4A), supporting the notion that
all the posttranslational modifications are present within the
2,508-Da mutacin 1140 product. The predominant mass of the
mutant product was 1,936 Da (Table 2 and Fig. 4B and C). This
mass corresponds to a truncated mutacin 1140 peptide that has
been cleaved between S(	3) andTrp(	4). Furthermore, themass
of the product corresponds to a loss of dehydration on a serine or
a threonine residue. We have previously shown that a serine engi-
neered at the 	1 position or the P(4)A F(1)S strain does not
undergo dehydration (35), suggesting that the distance from ei-
ther the LanP or the new cleavage site is important for a dehydra-
tion modification. Therefore, a loss of dehydration in the trun-
cated core peptide product presumably occurs at S(	5).
The observation of the 2,508-Da peptide corresponds to a fully
modified core peptide that has two additional amino acids (S and
FIG 3 HPLC chromatograms of crude extracts obtained from modified
THyex medium inoculated with wild-type S. mutans JH1140 (A) and S. mu-
tans lanP (B). There was a more than 2-fold increase in the amount of prod-
uct isolated from the S. mutans lanP strain. AU, absorbance units.
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R) from the leader peptide, while the 1,936-Da peptide corre-
sponds to a variant that has been cleaved at S(	3) and is lacking a
dehydrated Dha or Dhb residue. Given the observation of two
distinct cleavage sites in the(7–2)mutant, there is a possibility
that the 2,508-Da peptide fragment has been cleaved at both
A(3) and S(	3) but is being held together by the thioether link-
age in ring A. The lack of a single dehydration on the 1,936-Da
fragment enabled us to test this assumption by 2-mercaptoethanol
(BME) derivatization of the two products. The lanthionine rings,
the unsaturated amino acids Dha and Dhb, and the aminovinyl-
cysteine residues are susceptible to the addition of BME. The
2,508- and 1,936-Da peptides have seven and six modifiable posi-
tions, respectively. If there is no proteolytic cleavage between
S(	3) and Trp(	4), derivatization of both the 2,508-Da and the
1,936-Da peptides should increase by78Da for each addition of
BME. If there is a proteolytic cleavage between S(	3) and
Trp(	4) of the 2,508-Da peptide, derivatization would provide a
mass profile similar to that of the derivatized 1,936-Da peptide.
The latter scheme was observed following BME derivatization
(Fig. 4D). Given the absence of dehydration and the presence of a
free thiol in the 1,936-Da peptide product, there would be an
approximately 16-Da lower mass for each addition of BME to the
2,508-Da peptide product. The mass difference of 16 Da is attrib-
uted to the lack of dehydration within the 1,936-Da fragment and
the loss of 2 Da from the formation of a disulfide linkage between
BME and the free thiol on the cysteine within the 1,936-Da frag-
ment. The addition of two to six BMEs was observed by
MALDI-MS (Fig. 4D).
Transport of mutacin 1140. Mutations were engineered to
disrupt the formation of ring A, ring B, ring C, ring D, and com-
bined rings AB and CD (Fig. 2A and D). Alanine residues were
substituted for the cysteines in rings A, B, and C. Given that the
C-terminal cysteine is decarboxylated by LanD, an alanine was
substituted for the serine in ring D. Three distinct peptides were
isolated from the culturemedium for the ring Amutant (Table 2).
A 2,250-Da peptide corresponds to the core peptide that has not
undergone dehydration on one of its serine or threonine residues.
The 2,232-Da peptide corresponds to the core peptide that has
undergone dehydration on all of its serine and threonine residues.
A truncated core peptide with a mass of 1,702 Da corresponds to
mutacin 1140 with the loss of FKSW from the N-terminal end.
The mass of the major peptide identified in the ring Bmutant was
2,250 Da, followed by a peptide with a mass of 2,232 Da, corre-
sponding to the lack of a single dehydration within the core pep-
TABLE 2 MALDI-MS data for isolated products from S. mutansa
Strain Mass(es) (Da) Leader sequence(s)
S. mutans ATCC 55676 2,264.63 1 None
S. mutans lanP 3,164.50 1 SNDDPDTR
S. mutans A(9)F lanP 3,164.50 1 SNDDPDTR
S. mutans S(8)A lanP 3,148.50 1 ANDDPDTR
S. mutans S(8)F lanP 3,224.60 1 FNDDPDTR
S. mutans (8) lanP 2,963.32 1, 3,077.42 1 DDPDTR, NDDPDTR
S. mutans S(8)P lanP 3,457.90 1, 3,660.12 1 IVAPNDDPDTR, TTIVAPNDDPDTR
S. mutans N(7)P lanP 3,430.74 1, 3,632.75 1, 3,317.66 1, 3,218.59 1,
3,147.51 1, 2,963.42 1
IVASPDDPDTR, TTIVASPDDPDTR,
VASPDDPDTR, ASPDDPDTR,
SPDDPDTR, DDPDTR
S. mutans N(7)A lanP 3,121.47 1 SADDPDTR
S. mutans D(6)A lanP 3,120.49 1 SNADPDTR
S. mutans D(5)A lanP 3,120.49 1 SNDAPDTR
S. mutans P(4)A 2,264.63
S. mutans P(4)A lanP 3,138.46 1 SNDDADTR
S. mutans P(4)A F(1)Ser 2,204.53 1 ND
S. mutans P(4)A F(1)Ser lanP 3,078.36 1 SNDDADTR
S. mutans D(3)A lanP 3,120.49 1 SNDDPATR
S. mutans T(2)A lanP 3,134.47 1 SNDDPDAR
S. mutans R(1)A 3,079.39 1 SNDDPDTA
S. mutans R(1)A lanP 3,079.39 1 SNDDPDTA
S. mutans R(1)H 2,245.58 1 ND
S. mutans R(1)H lanP 3,145.45 1 SNDDPDTH
S. mutans (7–2) 1,936.23 1, 2,507.76 1 None, SR
S. mutans (7–2) lanP 1,936.23 1, 2,507.76 1 None, SR
S. mutans C6His ND ND
S. mutans C(7)A (ring A) 1,699.83 1, 2,250.58 1, 2,232.57 1 ND
S. mutans C(11)A (ring B) 2,250.58 1, 2,278.57 1, 2,232.57 1 ND
S. mutans C(21)A (ring C) 2,232.57 1 ND
S. mutans S(19)A (ring D) ND ND
S. mutans C(7)A C(11)A 2,218.52 1, 1,943.17 1, 3,100.49 1 SNDDPDTR
S. mutans C(21)A S(19)A ND ND
S. mutans lanT 2,264.63 1 ND
S. mutans lanP lanT 2,849.23 1, 3,165.50 1, 3,448.87 1, 2,964.31 1,
2,894.24 1, 2,637.02 1, 2,567.00 1
DPDTR, SNDDPDTR, IVASNDDPDT
R, DDPDTR, DPDTR, DTR, TR
a Some mutant strains produced more than one product. The product masses are listed in the order of the highest to the lowest relative peak intensity. Some mutant products were
not detectable (ND), and this information is indicated.
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tide and a core peptide that has undergone all dehydrations, re-
spectively (Table 2). There was an additional peptide with a mass
of 2,278 Da. This corresponds to a core peptide that has under-
gone all dehydrations and lacks a C-terminal decarboxylation.
The ring C mutant had only one peptide product with a mass of
2,232Da, which is themass of the core peptide that has undergone
all dehydrations (Table 2). There was no discernible product from
the ring Dmutant for which to obtain a mass (Fig. 5). The forma-
tion of ring D appears to be absolutely necessary for transport.
Ring A, ring B, and ring C mutants yielded approximately 60%,
90%, and 30% of the product, respectively, compared to the
amount of the product from the wild-type JH1140 strain on the
basis of the peak volumemeasurements determined by RP-HPLC
chromatograms. The ring A and Bmutant yielded levels similar to
those of the ring A mutant, and the ring C and D mutant had no
measurable product, as was the case for the ring D mutant. The
ring A, ring D, ring A and B, and ring C and D mutants had no
inhibitory activity (Fig. 2D). The ring B and ring C mutants had
approximately 65% and 35% reductions in activity, respectively.
The bioactivity of the S. mutans lanT strain was evaluated,
and it was found to be active in our deferred antagonism assay.
The lack of the mutacin 1140 transporter resulted in only an ap-
proximately 20% reduction in activity. The product isolated from
this strain had the predicted 2,265-Damass, suggesting that it had
undergone all of the posttranslationalmodifications. These results
show that there is an alternative transporter within S. mutans
JH1140 that can transportmutacin 1140. Given the importance of
the ringD regionwithin the core peptide for transport (Fig. 5), the
alternative transporter in S. mutans JH1140 must also depend on
the ring D region for transport. A strain with the double deletion
of lanP and lanTwas generated to evaluate the nature of the leader
peptide. Several peptide products that correspond to the core pep-
FIG 4 Characterization of the leader peptide (7–2) mutant. (A) Overlay assay using M. luteus as an indicator strain. From the top left to the bottom right,
spotting of 5 l of purified mutacin 1140 (10 g/ml) in acetonitrile-water (1:1), spotting of 5 l of acetonitrile (ACN)-water (1:1; negative control), deferred
antagonism assay of S. mutans (7–2), deferred antagonism assay of S. mutans lanP(7–2), spotting of 5 l of the product from S. mutans (7–2)
digested with trypsin, and spotting of 5 l of the product from S. mutans lanP (7–2) digested with trypsin. (B) MALDI-MS data for the product from S.
mutans(7–2). (C)MALDI-MS data for the product from S.mutanslanP(7–2). (D)MALDI-MS data for the BMEderivatization of the products isolated
from the S. mutans (7–2) strain.
FIG 5 Transport efficiencies of mutacin 1140 core peptide variants. Alanine
substitutions were made to disrupt ring A [C(7)A], ring B [C(11)A], ring C
[C(21)A], ring D [S(19)A], rings A and B [C(7)A C(11)A], and rings C and D
[S(19)A C(21)A]. Three independent extractions of each mutant strain were
characterized by RP-HPLC at 220 nm. The peak volumes of the variants of the
mutacin 1140 fractions were compared to the peak volume of wild-type strain
JH1140 and are presented as the percentage of the product relative to the
amount for the wild-type strain. The Student t test was used for statistical
analysis, and the asterisks signify statistical significance (P
 0.05).
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tide containing a leader peptide of 2 to 10 amino acids were iso-
lated (Table 2). The variation in peptide length is similar to that
observed with our peptides with proline mutations within the
secondary cleavage site.
DISCUSSION
In this study, we investigated the role of structural regions within
the leader peptide and core peptide in biosynthesis. The mutacin
1140 leader peptide sequence is different and longer than the
leader peptide sequences of other lantibiotics, while the core pep-
tide sequence is similar to the core peptide sequences of nisin,
epidermin, and gallidermin. Abetter understanding of the biosyn-
thesis of all lantibiotics will allow us to advance the use of the PTM
enzymes for protein chemistry applications and the design of
novel peptide-based therapeutics. We show that secondary cleav-
age, PTM enzymemodifications, and transport are highly coordi-
nated activities. Terminal core peptide ring formations are essen-
tial for transport, and the coordinated cleavage at the9 position
is dependent upon the presence of the LanT transporter. LanP
tolerates amino acid substitutions surrounding the primary cleav-
age site at position1.
A proline usually denotes a site of importance, given that it
confers breaks in secondary structure and causes turns in peptides
or proteins. The P(4)A mutation resulted in no significant loss
of bioactivity. This observation suggests that there is no secondary
structure within this region of the leader peptide and that this
region is not important for PTM enzyme activity. Furthermore,
there was no significant loss of bioactivity or notable interference
with the activities of the LanB, LanC, LanD, and LanP PTM en-
zymes with the removal of the proline [P(4)A] or the insertion
of prolines [S(8)P orN(7)P].We observed a slight statistically
significant loss of activity only with the T(2)A substitution.
However, the bioactivity andmass of the isolatedT(2)Aproduct
show that it has undergone all dehydrations and decarboxylation.
Secondary structure predictions suggest that the C-terminal end
of the leader peptide is a random coil. The findings of our muta-
tional study also suggest that this region is functionally unstruc-
tured. We believe that the unstructured region enables the inter-
action of the core peptide with the PTM enzyme active sites, while
the upstream box motif of the leader peptide is tethered to a PTM
enzyme binding site. This is supported by the cocrystal structure
ofNisA andNisB (29). The distinct leader peptide binding site and
the flexibility of leader peptide residues1 to8, along with the
flexibility of the core region, enable the core peptide to reach
the active site for glutamate elimination. Interestingly, following
the disruption of ring B formation in mutacin 1140, we saw a
variant that contained a C-terminal carboxyl group. This varia-
tion suggests that the core peptide was not efficiently processed by
the LanD decarboxylase. The inefficiency of decarboxylation ac-
tivity supports the concept that PTM enzymemodifications occur
under the dynamics of core peptide interaction with the PTM
enzyme active sites, guided by coordinated PTMs on the core pep-
tide.
We saw at least a 2-fold increase in the amount of product
isolated from the lanP deletion strain. One possible explanation
for this increase in activity could be attributed to a decrease in the
level of association of the product with the bacterial cell. The short
leader core peptide fusion may not readily bind to the cell enve-
lope, and the lack of binding would facilitate our extraction of the
peptide from the medium. Previous studies with mutacin 1140
suggest that a significant amount of the antibiotic is associated
with the cell pellet (44). Another possibility that we are exploring
is whether the removal of the leader peptide from the core peptide
has an inhibitory role in the production of mutacin 1140 or
whether the leader peptide bound to core peptide is an activator of
mutacin 1140 production.
The lack of specificity for both the upstream residues at posi-
tions 7 to 2 and the F at position 	1, near the cleavage site,
indicates that the protease does not require the recognition of a
specific amino acid sequence near the cleavage site of the leader
peptide. The specificity of cleavage by the LanP protease is un-
known. It has been suggested that the specificity can come from
structural elements within the core peptide or regions farther up-
stream of the core peptide or the protease recognizes the tertiary
structure of the truncated leader peptide and core peptide. The
latter explanation is unlikely, given that the P(4)A substitution
did not result in any loss of activity and that this region is predicted
to be unstructured. Furthermore, the recognition of a region up-
stream of S(8) is not likely, given that the leader peptide is only
8 amino acids and given the presence of the secondary cleavage
site. Core peptide recognition by NisP for the cleavage of the
leader peptide has been suggested for nisin (7, 22, 45), and given
the current results, core peptide structure is important for the
specificity of mutacin 1140 leader peptide cleavage by LanP. Ad-
ditional studies will need to be done to determine whether LanP
can recognize unmodified core peptide or whether PTM enzyme
modifications are important for the recognition. The inability of
the LanP protease to process the 2,508-Da product’s SR leader
peptide when there was a cleavage at S(	3) of ring A suggests that
the opening of ring A prevented LanP cleavage. This is also sup-
ported by the observation of a TR leader peptide variant in the
lanT and lanP deletion strain that was not present in the lanT
deletion strain, suggesting that the short TR sequence was re-
moved by LanP. Therefore, the short leader peptide appears to be
recognized by LanP. Furthermore, themajor product in the ringA
mutant was a truncated fragment (1,699Da) of the leader peptide.
These data suggest that an intact ring A is important for the spec-
ificity of cleavage by LanP, or they suggest that the ring A mutant
product is susceptible to proteolytic cleavage by another protease.
It is possible for LanP to function in coordination with the trans-
porter LanT and that this interaction coordinates protease speci-
ficity. However, we have shown that LanP is efficient at processing
the removal of truncated leader peptides in the LanT deletion
strain.
The deletion of positions 7 to 2 resulted in cleavage within
the core peptide S(	3) and cleavage at A(3). This cleavage led
to the formation of two peptide products withmasses of 1,936 and
2,508 Da. The presence of the 2,508-Da fragment, which was also
cleaved after S(	3) and held together by a thioether linkage, sug-
gests that dehydration, cyclization, and secondary cleavage func-
tion in a highly coordinated fashion. In our proposed model, the
formation of the terminal lanthionine rings C and D stabilizes an
interaction with the transporter (LanT), and this interaction co-
ordinates the secondary cleavage at the9 position by an uniden-
tified protease or proteolytic domain. There are two possible sce-
narios for the formation of the 1,936- and 2,508-Da products. The
first scenario would involve a highly mobile leader peptide mov-
ing back and forth from LanB to LanC, enabling the coordination
of dehydration and ring formation before coordination of the sec-
ondary cleavage that would yield the 1,936- and 2,508-Da prod-
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ucts. A more simplified scenario would involve the binding of the
leader peptide at a single position in which the core peptide can be
acted upon by the PTM enzymes. This scenario would explain the
formation of ring A, followed by cleavage after S(	3) and a sub-
sequent lower-frequency cleavage after the 3 position that
would free the peptide for transport. Themutant with the deletion
frompositions7 to 2 presumably has a lower rate of dehydration
at S(	3), which prevents cyclase activity. Without the formation
of ring A, the peptide is cleaved and transported, yielding the
1,936-Da fragment. If ring A forms, the peptide is still cleaved at
the 	3 position within the ring but is not free to be transported
until an additional cleavage occurs after the 3 position. These
data support the view that secondary cleavage is a component
integral to the biosynthesis of mutacin 1140 and that the PTM
activity involving dehydration, cyclization, secondary cleavage,
and transport is a dynamic process acting on the core peptide in a
highly coordinated fashion.
Secondary cleavage of the leader peptide was observed in the
lanT and lanP deletion strain, albeit the cleavage appeared to be
disordered and led to the formation of a number of peptide prod-
ucts. This suggests that the transporter is involved in coordinating
the secondary cleavage site. The isolation of a 1,936-Da product
also suggests that transport of the core peptide is not directly de-
pendent on the leader peptide. Given that cleavage at the second-
ary site is independent of LanT, it is logical to assume that the
presence of the 1,936-Da product is recognized and the product is
transported without an attached leader peptide.
The fact that cleavage still occurred regardless of themutations
made in the leader peptide suggests that the new cleavage site on
the leader peptide is an integral component within the biosyn-
thetic pathway of mutacin 1140. The new cleavage site appears to
rely more on the length of the leader peptide sequence than the
actual amino acid composition, with the exception of the proline
insertions. It is possible that cleavage aids in the release of the
modified peptide from a PTM enzyme before transport or having
a truncated leader peptide results in a more energy-efficient ap-
proach for transporting the modified core peptide. Deletion of
lanT resulted in the production of a fullymodified product, but in
the background of the lanT and lanP deletion strain, the ordered
cleavage betweenA(9) and S(8) was not observed. This is sim-
ilar to the random cleavage observed in ourmutants with A(9)P
and S(8)P mutations. These mutations may interfere with the
efficiency of transport of the modified product, leaving it suscep-
tible to cleavage by cytoplasmic proteases before being trans-
ported. Furthermore, we observed a dependency on ring D for-
mation for the isolation of any product from the mutacin 1140
biosynthesis system. We believe that the interaction of the core
peptide with the transporter coordinates the ordered cleavage at
A(9) and the absence of LanT leads to a random secondary
cleavage within the leader peptide. S. mutans JH1140 contains an
alternative transporter that efficiently transports these products
out of the cell. A lantibiotic transporter in nonlantibiotic-produc-
ing strain S. mutans GS-5 has recently been reported (46). In this
study, the authors demonstrated that the transporter confers pro-
tection against two-component lantibiotics similar to haloduracin
and Smb. It is possible that lantibiotic transporters aremore wide-
spread in S. mutans, given their environmental exposure to lan-
tibiotic and nonlantibiotic bacteriocins.
To date, the biosynthesis of only a few lantibiotics has been
studied. Even though these studies have enriched our understand-
ing of the PTM enzymes, we have barely scratched the surface of
understanding how these enzymes coordinate their activities to-
ward the synthesis of a fully functional lantibiotic without the
production of a significant amount of side products. Studies with
the mutacin 1140 biosynthesis system and other lantibiotic bio-
synthesis systemswill promote our understanding of this dynamic
process. The structural variants isolated from our mutational
study support a simplifiedmodel formutacin 1140 biosynthesis, a
model in which the leader peptide binds to one locus that coordi-
nates the core peptide PTMs. PTMs on the core peptide would
occur under a dynamic process, dictated by the distance of mod-
ifiable residues from PTM enzyme active sites and core peptide
structural elements. The products isolated from our mutagenesis
study do not support the current consensus within the field for
class I lantibiotic biosynthesis, in which the leader peptide shuttles
the core peptide to each PTM enzyme and transporter. For in-
stance, the presence of products that were lacking dehydration or
C-terminal decarboxylation following disruption of ring A or ring
B formation supports the coordinated activities of PTM enzymes
following successive steps of core peptide modifications. Further-
more, a dedicated secondary cleavage site at A(9) is present. The
S(8) or (7–2) truncation mutation resulted in a concomi-
tant cleavage toward or within the core peptide, suggesting that
the secondary cleavage is coordinated by the binding of the leader
peptide upstream of the secondary cleavage site. Furthermore, the
truncation of the C-terminal portion of the leader peptide also
affected the rate of dehydration at S(	3) or cyclase activity, pre-
venting ring A formation. These results further support the idea
that the leader peptide is bound at one location and that the length
of the C-terminal portion of the leader peptide is important for
promoting an efficient interaction of the core peptide with the
PTM enzymes.
The study provides a functional model for the biosynthesis of
mutacin 1140 and other related lantibiotics. In this model, the
PTM enzymes and transporter function in a highly coordinated
fashion, while the binding of the leader peptide to one of the PTM
enzymes facilitates the core peptide’s interaction with the PTM
enzymes and transporter. Following the secondary cleavage of the
leader peptide at A(9), facilitated by interaction of the modified
core peptide with the LanT transporter, the remaining portion of
the leader peptide is released from the PTM enzyme and the core
peptide with the truncated leader peptide is exported. Further
studies of themutacin 1140 biosynthetic pathway are underway to
determine whether this model will satisfy all of our experimental
observations.
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